[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Konruns Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":208},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,63,87,107,127,147,166,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100629929","phase-2-kc1036-in-combination-with-pd-1-antibody-and-platinum-based-chemotherapy-for-first-line-advanced-esophageal-cancer-100629929",false,"NCT07481058","KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","A Phase II Clinical Study to Evaluate the Efficacy and Safety of KC1036 Combined With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Males or females aged 18 to 75 years;\n* Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;\n* Patients who have not received prior systemic anti-tumor therapy for the current recurrent or metastatic disease;\n* At least one measurable tumor lesion according to RECIST 1.1;\n* Eastern Cooperative Oncology Group performance status score of 0 or 1;\n* Life expectancy \\> 12 weeks;\n* BMI≥16.0 kg\u002Fm2;\n* Adequate bone marrow, renal, and hepatic function;\n* Female patients of childbearing potential with a negative blood pregnancy test completed within 7 days before the first dose;\n* Patients should participate in the study voluntarily and sign informed consent.\n\nExclusion Criteria:\n\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastasis;\n* Other malignancies within the past 5 years;\n* Known hypersensitivity to any monoclonal antibodies or chemotherapy components;\n* Gastrointestinal abnormalities;\n* High risk of bleeding or fistula due to tumor invasion of adjacent organs, or existing esophageal\u002Ftracheal fistula;\n* Cardiovascular and cerebrovascular diseases;\n* Prior therapy with anti-angiogenic drugs or immunotherapy; Systemic therapy, investigational drugs, or live vaccines within 4 weeks prior to the first dose; Palliative radiotherapy within 2 weeks or major surgery within 28 days prior to enrollment;\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n* Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1;\n* Active autoimmune disease or a history of autoimmune disease requiring systemic treatment;\n* Active infections, including severe infection (CTCAE \\> Grade 2) within 4 weeks, active tuberculosis, or positive status for HIV, HBV, or HCV;\n* Pregnant or lactating women;\n* Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study;\n* Other conditions assessed by the investigator that would increase safety risks or interfere with the study results.","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).",[27],"Esophageal Squamous Cell Carcinoma (ESCC)","RECRUITING","2026-03-18",{"date":31,"type":32},"2026-03-20","ACTUAL",{"date":34,"type":32},"2025-12-12",{"date":36,"type":21},"2028-12",{"name":38,"class":39},"Beijing Konruns Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":4},"100602069","phase-1-a-study-of-kc1086-in-patients-with-advanced-solid-tumors-100602069","NCT07118709","A Study of KC1086 in Patients With Advanced Solid Tumors","A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of KC1086 in the Patients With Advanced Recurrent or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed recurrent or metastatic solid tumors;\n2. Patients who have failed standard or conventional treatment or for whom no standard treatment is available( definition of treatment failure: intolerable toxic and side effects, disease progression during treatment recurrence after treatment);\n3. Participants with advanced recurrent, unresectable, and\u002For metastatic tumors must have evaluable or measurable lesions (according to RECIST 1.1)；\n4. Eastern Cooperative Oncology Group performance status score of 0 or 1;\n5. Life expectancy \\> 12 weeks;\n6. Adequate bone marrow, renal, and hepatic function;\n7. Patients should participate in the study voluntarily and sign informed consent.\n\nExclusion Criteria:\n\n1. Any patient who is known to have untreated central nervous system (CNS) metastasis;\n2. Other kinds of malignancies within 5 years;\n3. Gastrointestinal abnormalities;\n4. Cardiovascular and cerebrovascular diseases;\n5. Involved in other clinical trials within 4 weeks before enrollment;\n6. Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment;\n7. Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment;\n8. Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1;\n9. Severe infection within 4 weeks prior to enrollment;\n10. Uncontrolled massive ascites, pleural or pericardial effusion；\n11. Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy;\n12. Prior therapies with KAT6 inhibitors\n13. Pregnant or lactating women;\n14. Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study.\n15. Other patients are not eligible for enrollment assessed by investigators.",{"count":49,"type":21},66,[51],"PHASE1","The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1086 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into two parts: dose-escalation phase and dose-expansion phase.",[54],"Advanced Solid Tumors Cancer","NOT_YET_RECRUITING","2025-08-07",{"date":58,"type":32},"2025-08-12",{"date":60,"type":21},"2025-08",{"date":36,"type":21},{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":40},"100513846","phase-3-a-study-of-jincaopian-tablets-on-chronic-pelvic-pain-after-pelvic-inflammatory-disease-100513846","NCT05970783","A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease","A Multicenter, Randomized, Double-blind, Dose-parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Jincaopian Tablets in Subjects with Chronic Pelvic Pain After Pelvic Inflammatory Disease","Inclusion Criteria:\n\n* Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;\n* The average VAS score of pain in the week before enrollment is ≥4;\n* The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);\n* Women aged 18 to 50 (including 18 and 50) with a history of sexual life;\n* Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pelvic inflammatory disease (acute attack);\n* Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 6 months after the trial;\n* Previously diagnosed with cervical intraepithelial neoplasia, primary\u002Fsecondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;\n* Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis;\n* Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms;\n* Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages;\n* Received related treatment or took drugs with similar functions and indications within 14 days before the introduction;\n* Liver function: ALT or AST\\>1.5 times the upper limit of normal value；Renal function：Scr\\>1.0 times the upper limit of normal value;\n* Serum CA125 and erythrocyte sedimentation \\> 1.1 times the upper limit of normal value.\n* Combined with serious cardiovascular, cerebrovascular, hematopoietic system and other serious diseases;\n* Have an allergic history to the experimental drug;\n* Have a long history of alcoholism or drug abuse;\n* Intellectual disabilities or mental disorders;\n* Participated in other clinical trials within the past 3 months;\n* The investigator believes that it is not suitable to participate in this clinical trial.","FEMALE","50 Years",{"count":73,"type":21},414,[75],"PHASE3","The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease",[78],"Chronic Pelvic Pain","2024-10-15",{"date":81,"type":32},"2024-10-17",{"date":83,"type":32},"2022-11-08",{"date":85,"type":21},"2025-04",{"name":38,"class":39},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100491803","phase-2-a-study-of-kc1036-in-patients-with-advanced-thymic-tumors-100491803","NCT05683886","A Study of KC1036 in Patients with Advanced Thymic Tumors","A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors","Inclusion Criteria:\n\n* Patients with thymoma or thymic carcinoma confirmed by cytologically or histologically (WHO Classification of Thoracic Tumors 5th ed), including all pathological subtypes;\n* Patients with advanced recurrent, unresectable and\u002For metastatic thymic tumor as defined by the Masaoka-Koga stage;\n* Subsequent relapse of disease following first-line systemic chemotherapy;\n* Patients with at least one measurable lesion as defined by RECIST V1.1; Measurable lesions located within the radiation field of previous radiotherapy or after local treatment can also be selected as target lesions if progression is confirmed.\n* Eastern Cooperative Oncology Group performance status score of 0 or 1;\n* Life expectancy \\> 12 weeks;\n* Adequate organ and marrow function;\n* Patients should participate in the study voluntarily and sign informed consent.\n\nExclusion Criteria:\n\n* Patients with thymus neuroendocrine tumors;\n* Any patient who is known to have central nervous system (CNS) metastasis or imaging shows a risk of CNS metastasis;\n* Previous (within the last 5 years) or current malignancies at other sites;\n* Gastrointestinal abnormalities;\n* Cardiovascular and cerebrovascular diseases;\n* Patients who have previous treatment with small molecule VEGFR-TKI (except patients whose treatment cycle is less than 2 weeks due to intolerance or other reasons); Patients who have previous treatment with PD-1 \u002F PD-L1 antibody combined with small molecule VEGFR-TKI;\n* Involved in other clinical trials within 4 weeks before enrollment; Prior anti-tumor therapies with chemotherapy, cytotherapy, immunotherapy, operation (Interventional therapy excepted) within 4 weeks 4 weeks before enrollment; Prior radiotherapy (palliative radiotherapy excepted) within 2 weeks; Prior small-molecule targeted therapy within 2 weeks or 5 half-lives.\n* Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE V5.0 grade 0 or 1 with the exception of alopecia;\n* Skin wound, surgical site, wound site, mucous membrane severe ulcer or fracture comfirmed as having not recovered;\n* Uncontrolled mass pleural effusion, ascites, and pericardial effusion;\n* Active autoimmune diseases: Myasthenia gravis, pure red cell aplastic anemia, systemic lupus erythematosus, inflammatory bowel disease, etc;\n* Need immunosuppressive agents or hormone therapy for immunosuppression, , and still need immunosuppressive therapy within 2 weeks before enrollment;\n* Active bacterial, viral or fungal infection; Fever of unknown cause (\\> 38.5℃) occurred within 2 weeks before enrollment;\n* Patients who are positive for both Hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) quantification results; Patients who are positive for both hepatitis C virus antibody (HCAB) and hepatitis C virusribonucleic acid (HCV-RNA) quantification results; Patients who are positive for human immunodeficiency virus (HIV);\n* Pregnant or lactating women;\n* Patients who do not take contraception during the study period and within 6 months after the study;\n* Patients with insufficient compliance as evaluated by investigator;\n* The investigator believes that it is not suitable to patient in this clinical trial.",{"count":95,"type":21},30,[24],"This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.",[99],"Thymic Tumors",{"date":81,"type":32},{"date":102,"type":32},"2023-02-22",{"date":104,"type":21},"2026-02",{"name":38,"class":39},2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100459266","phase-1-to-evaluate-kc1036-in-the-patients-with-advanced-digestive-system-tumors-100459266","NCT05260385","To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors","A Phase Ib \u002F II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Digestive System Tumors","Inclusion Criteria:\n\n* Histologically or cytologically confirmed malignant digestive system tumors;\n* Patients with advanced recurrent, unresectable and \u002F or metastatic digestive system tumors who have failed standard or conventional treatment:( definition of treatment failure: intolerable toxic and side effects, disease progression during treatment recurrence after treatment);\n* Eastern Cooperative Oncology Group performance status score of 0 or 1;\n* Life expectancy \\> 12 weeks;\n* BMI≥18.0;\n* Has adequate Hematologic, renal, and hepatic function;\n* Patients should participate in the study voluntarily and sign informed consent.\n\nExclusion Criteria:\n\n* Any patient who is known to have central nervous system (CNS) metastasis with clinical symptoms;\n* Other kinds of malignancies;\n* Gastrointestinal abnormalitiest;\n* Cardiovascular and cerebrovascular diseases;\n* Previous treatment with small molecule vascular targeting inhibitor；\n* Prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks before enrollment;\n* Involved in other clinical trials within 4 weeks before enrollment;\n* Major surgical procedure, open biopsy, or significant traumatic injury 4 weeks before enrollment;\n* Uncontrolled massive ascites,pleural\u002Fpericardial effusion;\n* Uncontrolled ongoing or active bacterial, viral or fungal infectious; Fever of unknown cause (\\> 38.5 ℃) occurred within 2 weeks before enrollment;\n* Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection ;\n* Pregnant or lactating women or those who do not take contraceptives, including men;\n* Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings;\n* Inability to comply with protocol required procedures.",{"count":115,"type":21},133,[51,24],"The purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of KC1036 in participants with advanced recurrent or metastatic digestive system tumors.",[119],"Digestive System Tumors",{"date":81,"type":32},{"date":122,"type":32},"2022-01-24",{"date":124,"type":21},"2025-12-30",{"name":38,"class":39},13,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100392278","phase-1-a-study-of-kc1036-in-patients-with-advanced-solid-tumors-100392278","NCT04387916","A Study of KC1036 in Patients with Advanced Solid Tumors","A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Histologically or cytologically confirmed recurrent or metastatic solid tumors;\n* Patients who have failed standard or conventional treatment, Including chemotherapy, targeted therapy, immunotherapy:\n\nDocumented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant\u002Fneoadjuvant therapy;\n\n* At least one measurable lesion (by RECIST 1.1);\n* Eastern Cooperative Oncology Group performance status score of 0 or 1;\n* Life expectancy \\> 12 weeks;\n* Patients should participate in the study voluntarily and sign informed consent.\n\nExclusion Criteria:\n\n* Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks;\n* Other kinds of malignancies;\n* Hematologic, renal, and hepatic function abnormities;\n* Risk of bleeding;\n* Gastrointestinal abnormalitiest;\n* Cardiovascular and cerebrovascular diseases;\n* Prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks of enrollment;\n* Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE V5.0 grade 0 or 1 with the exception of alopecia;\n* Involved in other clinical trials within 4 weeks of enrollment;\n* Major surgical procedure, open biopsy, or significant traumatic injury 4 weeks days of enrollment;\n* History of organ allograft;\n* Need immunosuppressive agents or systemic or absorbable topical hormone therapy for immunosuppression;\n* Uncontrolled ongoing or active infection;\n* Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy;\n* Pregnant or lactating women or those who do not take contraceptives, including men;\n* Suffering from mental and neurological diseases;\n* Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings;\n* Inability to comply with protocol required procedures.",{"count":135,"type":21},207,[51],"The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.",[139],"Advanced Solid Tumors",{"date":81,"type":32},{"date":142,"type":32},"2020-09-04",{"date":144,"type":21},"2025-12-31",{"name":38,"class":39},3,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":40},"100369678","phase-1-a-phase-1-study-of-cx1003-kanitinib-in-patients-with-advanced-solid-tumors-100369678","NCT04093466","A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors","A Phase 1, Multicenter, Open-label, Dose Escalation\u002Fexpansion Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of CX1003 (Kanitinib) in the Patients with Relapsed Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Histologically or cytologically confirmed recurrent or metastatic solid tumors;\n* At least one measurable lesion (spiral CT scan long diameter ≥10 mm or enlarged lymph node short diameter ≥15 mm by RECIST 1.1);\n* Documented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant\u002Fneoadjuvant therapy;\n* ECOG PS ≤1;\n* Expected overall survival≥12 weeks;\n\nExclusion Criteria:\n\n* Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks;\n* Other kinds of malignancies \\[excluding stage IB or lower grade cervical cancer，noninvasive basal cell or squamous cell cancer, breast cancer with complete remission (CR) \\> 10 years ,melanoma with CR \\> 10 years or other malignant tumors with CR \\> 5 years\\];\n* Hematologic, renal, and hepatic function abnormities as defined below:\n\nAbsolute neutrophil count (ANC) \\\u003C1.5×109 \u002FL or platelet \\\u003C100×109 \u002FL or hemoglobin \\\u003C9 g\u002FdL; Total bilirubin \\> 1.5×the upper limit of normal range(ULN) without liver metastases; total bilirubin \\> 3×ULN with liver metastases; AST, ALT, ALP \\>1.5×ULN without liver metastases ; AST, ALT, ALP \\>5×ULN with liver metastases; Primary hepatocellular carcinoma; Hepatic cirrhosis with Child-Pugh B or C; Serum creatinine \\>1.5×ULN; History of previous nephrotic syndrome; INR or aPPT \\>1.5×ULN; Presence of hemorrhage (hemoptysis) , thrombosis，or currently receiving treatment with warfarin, aspirin, low molecular weight heparin (LMWH), or any other anti-platelet drugs (Aspirin ≤100 mg\u002Fd for prophylaxis are allowed); •Any of the following gastrointestinal disease: Unable to swallow oral drugs; Need intravenous nutrition; History of a gastric resection; History of treatment for active peptic ulcer disease within 6 months; Clinically significant gastrointestinal bleeding within 3 months; Persistent grade 2 or higher chronic diarrhea despite optimal medical management;\n\n•Any of the following cardiovascular and cerebrovascular disease: Myocardial infarction , severe cardiac arrhythmias, unstable angina, coronary artery disease, congestive heart failure, cerebrovascular accident or TIA within 12 months ; Deep vein thrombosis or pulmonary embolism within 6 months; QTcF \\>470 msec; Uncontrolled hypertension despite optimal medical management;\n\n* Presence of unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 grade 0 or 1 with the exception of alopecia;\n* Involved in other clinical trials within 30 days of enrollment;\n* Major surgical procedure, open biopsy, or significant traumatic injury within 30 days of enrollment;\n* History of organ allograft ;\n* Need glucocorticoids or other immunosuppressive agents for immunosuppression (excluding local or inhaled glucocorticoids);\n* Uncontrolled ongoing or active infection;\n* Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy;\n* Pregnant or lactating women or those who do not take contraceptives, including men;\n* Suffering from mental and neurological diseases;\n* Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings;\n* Inability to comply with protocol required procedures.",{"count":155,"type":21},126,[51],"CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR\u002FMET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.",[159],"Advanced Solid Tumor",{"date":81,"type":32},{"date":162,"type":32},"2020-04-27",{"date":164,"type":21},"2025-12",{"name":38,"class":39},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":17,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":40},"100559449","phase-2-a-study-of-kc1036-in-adolescents-with-advanced-ewing-sarcoma-100559449","NCT06564272","A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","A Phase II Study to Evaluate the Safety and Efficacy of KC1036 in Adolescents Aged 12 and Above With Advanced Ewing Sarcoma","Inclusion Criteria:\n\n* Age between 12 and less than 18 years;\n* Diagnosed with Ewing sarcoma confirmed by histopathological examination;\n* Patients with locally advanced or metastatic Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator;\n* Body weight of ≥30 kg;\n* Karnofsky performance status (≥16 years) or Lansky performance status (\\\u003C16 years) score of ≥60%;\n* Patients with at least one measurable lesions according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors);\n* Expected survival of more than 12 weeks;\n* Sufficient organ and bone marrow function;\n* Female patients who have started menstruating must have a negative pregnancy test;\n* The patient and their legal guardians understand and are willing to participate in the trial, and have signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with primary central nervous system tumors;\n* Presence of central nervous system metastases as diagnosed by imaging;\n* History of or concurrent other malignancies within the past 5 years;\n* Gastrointestinal abnormalities;\n* Cardiovascular or cerebrovascular abnormalities;\n* Patients who have previously received VEGFR-TKI small molecule treatment;\n* Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;\n* Underwent major surgery within 2 months before enrollment or have not fully recovered, or plan to undergo surgery during the current study period;\n* Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to CTCAE v5.0), excluding alopecia;\n* Unhealed skin wounds, surgical sites, traumatic sites, severe mucosal ulcers, or fractures;\n* Uncontrolled significant pleural effusion, ascites, or pericardial effusion;\n* Active bacterial, viral, or fungal infections; unexplained fever \\>38.5°C within 2 weeks before enrollment;\n* Hepatitis B surface antigen (HBsAg) positive with HBV-DNA ≥500 IU\u002FmL or 2500 copies\u002FmL; Hepatitis C virus (HCV) antibody positive with HCV RNA ≥200 IU\u002FmL or positive test results; HIV-positive individuals;\n* Presence of psychiatric or neurological disorders; or cognitive impairment;\n* Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use contraception (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;\n* Patients with insufficient compliance as evaluated by investigator;\n* The investigator believes that it is not suitable to patient in this clinical trial.","12 Years",{"count":95,"type":21},[24],"This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.",[178],"Ewing Sarcoma","2024-08-21",{"date":181,"type":32},"2024-08-23",{"date":183,"type":21},"2024-09-27",{"date":185,"type":21},"2028-04-01",{"name":38,"class":39},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":40},"100531049","phase-3-a-study-of-kc1036-versus-investigators-choice-of-chemotherapy-in-patients-with-advanced-esophageal-cancer-100531049","NCT06194734","A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Males or females aged 18 to 75 years;\n* Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;\n* Patient with advanced recurrent or metastatic esophageal squamous cell carcinoma previously treated with a PD-1 or PD-L1 inhibitor and at least second-line systemic therapy;\n* At least one measurable tumor lesion according to RECIST 1.1;\n* Eastern Cooperative Oncology Group performance status score of 0 or 1;\n* Life expectancy \\> 12 weeks;\n* BMI≥16.0 and weight≥40 kg ;\n* Adequate bone marrow, renal, and hepatic function;\n* Female patients of childbearing potential with a negative blood pregnancy test completed within 7 days before randomization；\n* Patients should participate in the study voluntarily and sign informed consent.\n\nExclusion Criteria:\n\n* Any patient who is known to have untreated central nervous system (CNS) metastasis;\n* Other kinds of malignancies within 5 years;\n* Gastrointestinal abnormalities;\n* Cardiovascular and cerebrovascular diseases;\n* Prior therapies with vascular targeting inhibitor；\n* Previously treated with Irinotecan, Docetaxel and Tegafur Gimeracil Oteracil Potassium；\n* Involved in other clinical trials within 4 weeks before enrollment；Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment;Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment;\n* Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1;\n* Uncontrolled massive ascites, pleural or pericardial effusion;\n* Severe infection within 4 weeks prior to randomization (CTCAE \\> Grade 2);\n* Known history of human immunodeficiency virus (HIV) infection or current active hepatitis B or C infection;\n* Pregnant or lactating women;\n* Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study.\n* Other patients are not eligible for enrollment assessed by investigators.",{"count":195,"type":21},490,[75],"The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma",[199],"Esophageal Squamous Cell Carcinoma","2024-03-06",{"date":202,"type":32},"2024-03-07",{"date":204,"type":32},"2024-02-05",{"date":206,"type":21},"2027-12-30",{"name":38,"class":39},""]